Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company

BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline

Fineline Cube Nov 23, 2024

On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...

Company

Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies

Fineline Cube Nov 23, 2024

On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...

Company Drug

HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC

Fineline Cube Nov 22, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...

Company Drug

First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors

Fineline Cube Nov 22, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...

Company Drug

Bayer’s Nubeqa Files for FDA Approval in mHSPC

Fineline Cube Nov 22, 2024

German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...

Company

MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion

Fineline Cube Nov 22, 2024

The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...

Company Deals

Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China

Fineline Cube Nov 22, 2024

China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...

Company Drug

China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors

Fineline Cube Nov 22, 2024

China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD;...

Company

Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance

Fineline Cube Nov 22, 2024

US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second...

Company Deals

Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements

Fineline Cube Nov 22, 2024

The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company...

Company Drug

Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K

Fineline Cube Nov 22, 2024

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...

Company Drug

Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment

Fineline Cube Nov 22, 2024

Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...

Company Deals

Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib

Fineline Cube Nov 22, 2024

US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study

Fineline Cube Nov 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion

Fineline Cube Nov 22, 2024

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...

Company Drug

InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China

Fineline Cube Nov 22, 2024

China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the...

Company Deals

Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics

Fineline Cube Nov 22, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...

Company Deals Drug

Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing

Fineline Cube Nov 22, 2024

China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...

Company Medical Device

United Imaging Installs AI-Powered uMR OMEGA at XRANM’s Breast Health Center

Fineline Cube Nov 22, 2024

Shanghai-based United Imaging Healthcare Co., Ltd. has announced the installation of an ultra-wide-bore AI-empowered uMR...

Company Drug

Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA

Fineline Cube Nov 21, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...

Posts pagination

1 … 283 284 285 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.